the demise of csl, page-8

Suzy Jones was previously Head of Business Development @ Genetech prior to it's aquisition by Roche for $45B in 2009, don't forget Genetech was a company twice the size of CSL.

So why would Suzy Jones previously the head of business development at a multi billion dollar pharmaceutical company come here? with a micro cap of $11M but a portfolio of novel human antibody treatments for cancer entering clinical trials & setting up to be outlicensed.

I highly doubt she came because the science sucked

Make up your own minds.